Company: MBIO
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001410578-25-000085
Chunk: 271

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-07
Form: 424B4
Chunk 271
---
 $0.6 million and $1.6 million, respectively, and was recorded in research and development expense in the Unaudited Statements of Operations. Impairment of Long-Lived Assets During the second quarter of fiscal year 2024, the Company concluded it had a triggering event requiring assessment of impairment for certain leasehold improvements and the related right-of-use asset. The Company assessed the carrying value of the asset group consisting of the leasehold improvements and right-of-use asset in accordance with ASC 360, given the significant changes to the Company’s operations, operating cash and the repurchase of equipment. The assessment of the recoverability of the asset group concluded that there was impairment on the carrying value of the asset group of approximately $2.6 million, which was allocated on a pro rata basis using the relative carrying amounts of the assets. Approximately $2.2 million of the impairment loss was allocated to the leasehold improvements, with the remaining $0.4 million allocated to the right-of-use asset. Note 7 - Accounts Payable and Accrued Expenses At September 30, 2024, and December 31, 2023, accounts payable and accrued expenses consisted of the following:

| ​                                           
 ($ in thousands)                            | ​ 
 ​ 
 ​ | ​    
 ​    
 2024 |             ​ 
 September 30, | ​ | ​    
 ​    
 2023 |            ​ 
 December 31, | ​ 
 ​ |
|:--------------------------------------------|:--|:-----|--------------:|:--|:-----|-------------:|:--|
| Accounts payable                            | ​ | $    |         8,759 | ​ | $    |        6,322 | ​ |
| Accrued research and development            | ​ | ​    |           561 | ​ | ​    |        4,118 | ​ |
| Accrued compensation                        | ​ | ​    |           984 | ​ | ​    |        2,838 | ​ |
| Other (1)                                   | ​ | ​    |         1,757 | ​ | ​    |          739 | ​ |
| Total accounts payable and accrued expenses | ​ | $    |        12,061 | ​ | $    |       14,017 | ​ |

(1)Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5. Note 8 – Notes Payable On